Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.
Zag Bio has raised $80.0M in total funding. The most recent round was Series A. The last funding was announced in October 2025.
Zag Bio's investors include Lightspeed Venture Partners, Pear VC, AbbVie, Sanofi Ventures, Polaris Partners.
Zag Bio is headquartered in Cambridge, United States.
Zag Bio is a biotechnology company that designs thymus-targeting bifunctional antibody medicines to treat and prevent autoimmune diseases.
Zag Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Zag Bio — Funding & Investors." VCBacked, October 28, 2025, https://www.vcbacked.co/company/zag-bio. Accessed August 15, 2026.
VCBacked. (2025). Zag Bio — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/zag-bio
{{cite web |title=Zag Bio — Funding & Investors |url=https://www.vcbacked.co/company/zag-bio |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated